SE0400235D0 - New composition containing quinoline compounds - Google Patents
New composition containing quinoline compoundsInfo
- Publication number
- SE0400235D0 SE0400235D0 SE0400235A SE0400235A SE0400235D0 SE 0400235 D0 SE0400235 D0 SE 0400235D0 SE 0400235 A SE0400235 A SE 0400235A SE 0400235 A SE0400235 A SE 0400235A SE 0400235 D0 SE0400235 D0 SE 0400235D0
- Authority
- SE
- Sweden
- Prior art keywords
- salt
- formula
- composition containing
- new composition
- quinoline compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0400235A SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | New composition containing quinoline compounds |
KR1020127013996A KR20120062029A (ko) | 2004-02-06 | 2005-02-04 | 퀴놀린 화합물을 포함하는 신규 조성물 |
AP2006003674A AP2395A (en) | 2004-02-06 | 2005-02-04 | New composition containing quinoline compounds. |
DK05707942.8T DK1720531T3 (da) | 2004-02-06 | 2005-02-04 | Nye sammensætninger indeholdende quinolinforbindelser |
US11/050,441 US7589208B2 (en) | 2004-02-06 | 2005-02-04 | Compositions containing quinoline compounds |
ES05707942T ES2364754T3 (es) | 2004-02-06 | 2005-02-04 | Nuevas composiciones que contienen compuestos de quinolina. |
UAA200608964A UA90463C2 (ru) | 2004-02-06 | 2005-02-04 | Композиция, содержащая соединения хинолина |
DE602005027445T DE602005027445D1 (de) | 2004-02-06 | 2005-02-04 | Neue zusammensetzungen mit chinolin-verbindungen |
CN2005800038879A CN1980669B (zh) | 2004-02-06 | 2005-02-04 | 含喹啉化合物的新组合物 |
PT05707942T PT1720531E (pt) | 2004-02-06 | 2005-02-04 | Novas composições contendo compostos de quinolina |
SI200531327T SI1720531T1 (sl) | 2004-02-06 | 2005-02-04 | Novi sestavki, ki vsebujejo kinolinske spojine |
NZ548469A NZ548469A (en) | 2004-02-06 | 2005-02-04 | Solid pharmaceutical formulation containing a salt of a 3-quinoline carboxamide derivative |
PL05707942T PL1720531T3 (pl) | 2004-02-06 | 2005-02-04 | Nowe kompozycje zawierające związki chinoliny |
BRPI0506906-8A BRPI0506906B1 (pt) | 2004-02-06 | 2005-02-04 | Composição farmacêutica sólida estável contendo sal de um derivado de 3-quinolinacarboxamida, e processos para a estabilização de um sal, e para a preparação de um sal cristalino |
EP05707942A EP1720531B1 (en) | 2004-02-06 | 2005-02-04 | New compositions containing quinoline compounds |
RU2006132070/04A RU2339622C2 (ru) | 2004-02-06 | 2005-02-04 | Новые композиции, содержащие хинолиновые соединения |
AU2005210174A AU2005210174B2 (en) | 2004-02-06 | 2005-02-04 | New compositions containing quinoline compounds |
ZA200605619A ZA200605619B (en) | 2004-02-06 | 2005-02-04 | New compositions containing quinoline compounds |
KR1020067017639A KR101189557B1 (ko) | 2004-02-06 | 2005-02-04 | 퀴놀린 화합물을 포함하는 신규 조성물 |
CA2552463A CA2552463C (en) | 2004-02-06 | 2005-02-04 | New compositions containing quinoline compounds |
PCT/EP2005/050485 WO2005074899A2 (en) | 2004-02-06 | 2005-02-04 | New compositions containing quinoline compounds |
KR1020137000988A KR101457463B1 (ko) | 2004-02-06 | 2005-02-04 | 퀴놀린 화합물을 포함하는 신규 조성물 |
JP2006551857A JP4864724B2 (ja) | 2004-02-06 | 2005-02-04 | キノリン化合物を含有する新規な組成物 |
AT05707942T ATE505186T1 (de) | 2004-02-06 | 2005-02-04 | Neue zusammensetzungen mit chinolin-verbindungen |
IL176255A IL176255A (en) | 2004-02-06 | 2006-06-12 | New preparations containing quinoline compounds |
NO20063931A NO337235B1 (no) | 2004-02-06 | 2006-09-04 | Nye sammensetninger inneholdende kinolinforbindelser |
HK07111206.0A HK1105866A1 (en) | 2004-02-06 | 2007-10-17 | New compositions containing quinoline compounds |
US12/405,413 US8314124B2 (en) | 2004-02-06 | 2009-03-17 | Crystalline salts of quinoline compounds and methods for preparing them |
CY20111100676T CY1111697T1 (el) | 2004-02-06 | 2011-07-12 | Νεες συνθεσεις οι οποιες περιεχουν ενωσεις κινολινης |
US13/669,920 US8754104B2 (en) | 2004-02-06 | 2012-11-06 | Crystalline salts of quinoline compounds and methods for preparing them |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0400235A SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | New composition containing quinoline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0400235D0 true SE0400235D0 (sv) | 2004-02-06 |
Family
ID=31885235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0400235A SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | New composition containing quinoline compounds |
Country Status (26)
Country | Link |
---|---|
US (1) | US7589208B2 (sv) |
EP (1) | EP1720531B1 (sv) |
JP (1) | JP4864724B2 (sv) |
KR (3) | KR20120062029A (sv) |
CN (1) | CN1980669B (sv) |
AP (1) | AP2395A (sv) |
AT (1) | ATE505186T1 (sv) |
AU (1) | AU2005210174B2 (sv) |
BR (1) | BRPI0506906B1 (sv) |
CA (1) | CA2552463C (sv) |
CY (1) | CY1111697T1 (sv) |
DE (1) | DE602005027445D1 (sv) |
DK (1) | DK1720531T3 (sv) |
ES (1) | ES2364754T3 (sv) |
HK (1) | HK1105866A1 (sv) |
IL (1) | IL176255A (sv) |
NO (1) | NO337235B1 (sv) |
NZ (1) | NZ548469A (sv) |
PL (1) | PL1720531T3 (sv) |
PT (1) | PT1720531E (sv) |
RU (1) | RU2339622C2 (sv) |
SE (1) | SE0400235D0 (sv) |
SI (1) | SI1720531T1 (sv) |
UA (1) | UA90463C2 (sv) |
WO (1) | WO2005074899A2 (sv) |
ZA (1) | ZA200605619B (sv) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100891887B1 (ko) | 2001-01-29 | 2009-04-03 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
EA011862B1 (ru) * | 2004-03-24 | 2009-06-30 | Актавис Груп Хф. | Композиции рамиприла |
RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
BRPI0617477A2 (pt) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
GB2431579A (en) * | 2005-10-28 | 2007-05-02 | Arrow Int Ltd | Ramipril formulations |
LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
AU2013201426B2 (en) * | 2005-12-28 | 2016-06-02 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2016219571B2 (en) * | 2005-12-28 | 2018-03-15 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
PT2035001E (pt) * | 2006-06-12 | 2012-02-06 | Teva Pharma | Preparações de laquinimod estáveis |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
KR20100097145A (ko) * | 2007-11-27 | 2010-09-02 | 오하라 야꾸힝 고교 가부시키가이샤 | 조립물의 제조 방법 |
PT2234485E (pt) | 2007-12-20 | 2014-02-17 | Teva Pharma | Preparações de laquinimod estáveis |
WO2010001257A2 (en) * | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
WO2010065969A1 (en) * | 2008-12-05 | 2010-06-10 | Abraxis Bioscience, Llc | Sparc binding scfcs |
DE102008064379A1 (de) * | 2008-12-22 | 2010-07-15 | Siemens Aktiengesellschaft | Magnetspulenanordnung mit festen und beweglichen Spulen |
DK2408750T3 (en) | 2009-03-20 | 2015-10-05 | Vertex Pharma | PROCESS FOR THE PREPARATION modulators of cystic fibrosis -TRANSMEMBRANKONDUKTANSREGULATOR |
JP5503192B2 (ja) * | 2009-06-03 | 2014-05-28 | 大原薬品工業株式会社 | 生理活性物質含有粒子の製造方法 |
CN107308162A (zh) | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
ES2564931T3 (es) * | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
EP3064206B1 (en) | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
US20130035390A1 (en) | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
WO2011089623A2 (en) * | 2010-01-20 | 2011-07-28 | Cadila Healthcare Limited | Process for preparing pitavastatin and pharmaceutically acceptable salts thereof |
KR20160129093A (ko) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
JP5819328B2 (ja) | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
MX2012010950A (es) | 2010-03-23 | 2012-11-12 | Vifor Int Ag | Compuestos del complejo de fe (iii) para el tratamiento y profilaxis de los sintomas de deficienza de hierro y las anemias por deficiencia de hierro. |
WO2012006544A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
SG10201505236YA (en) | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
WO2012050500A1 (en) | 2010-10-14 | 2012-04-19 | Lars Pettersson | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
ES2548407T3 (es) | 2011-05-31 | 2015-10-16 | Vifor (International) Ag | Compuestos de complejos de 2,4-dioxo-1-carbonilo de Fe(III) para su uso en el tratamiento y la profilaxis de estados de deficiencia de hierro y anemias por deficiencia de hierro |
MX2014004420A (es) | 2011-10-12 | 2014-07-09 | Teva Pharma | Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod. |
AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
SG11201404419WA (en) | 2012-02-16 | 2014-10-30 | Teva Pharma | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
CA2891572A1 (en) | 2012-12-21 | 2014-06-26 | Vifor (International) Ag | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias |
EP2968203A1 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
RU2530626C1 (ru) * | 2013-10-21 | 2014-10-10 | Ооо "Валента-Интеллект" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
AU2015316824B2 (en) | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
US10300053B2 (en) | 2014-11-19 | 2019-05-28 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
KR20180065223A (ko) | 2016-12-07 | 2018-06-18 | 순천향대학교 산학협력단 | 천식의 치료 또는 완화용 약학 조성물 |
EP3837008A2 (en) | 2018-08-15 | 2021-06-23 | Pharmacyl AB | Substituted benzamides and their use in therapy |
AU2019322564A1 (en) | 2018-08-15 | 2021-03-25 | Pharmacyl Ab | A new medical treatment for pathologic inflammation |
BR112022023448A2 (pt) * | 2020-05-21 | 2023-01-31 | Stemsynergy Therapeutics Inc | Inibidores de notch e usos dos mesmos |
JP2023535021A (ja) | 2020-07-23 | 2023-08-15 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 骨髄増殖性腫瘍における新規治療用標的としてのs100タンパク質 |
AU2022208424A1 (en) | 2021-01-18 | 2023-08-24 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
US5077851A (en) * | 1989-02-27 | 1992-01-07 | Guma Juan M | Method and apparatus for treating corded fabrics |
SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
GB9402275D0 (en) * | 1994-02-07 | 1994-03-30 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
NZ324446A (en) | 1995-12-22 | 1999-08-30 | Kowa Co | Pharmaceutical composition containing (e)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropyl-quinolin -3'-yl]-6-heptenoic acid where the aqueous solution or dispersion of the composition has a ph of 7 to less than 8 |
WO1997041108A1 (en) * | 1996-04-30 | 1997-11-06 | Warner-Lambert Company | Substituted piperazines and piperidines as central nervous system agents |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
PL199781B1 (pl) * | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
-
2004
- 2004-02-06 SE SE0400235A patent/SE0400235D0/sv unknown
-
2005
- 2005-02-04 KR KR1020127013996A patent/KR20120062029A/ko not_active Application Discontinuation
- 2005-02-04 KR KR1020067017639A patent/KR101189557B1/ko active IP Right Grant
- 2005-02-04 EP EP05707942A patent/EP1720531B1/en active Active
- 2005-02-04 PT PT05707942T patent/PT1720531E/pt unknown
- 2005-02-04 RU RU2006132070/04A patent/RU2339622C2/ru not_active IP Right Cessation
- 2005-02-04 AP AP2006003674A patent/AP2395A/xx active
- 2005-02-04 CA CA2552463A patent/CA2552463C/en active Active
- 2005-02-04 UA UAA200608964A patent/UA90463C2/ru unknown
- 2005-02-04 KR KR1020137000988A patent/KR101457463B1/ko active IP Right Grant
- 2005-02-04 ZA ZA200605619A patent/ZA200605619B/en unknown
- 2005-02-04 WO PCT/EP2005/050485 patent/WO2005074899A2/en active Application Filing
- 2005-02-04 PL PL05707942T patent/PL1720531T3/pl unknown
- 2005-02-04 CN CN2005800038879A patent/CN1980669B/zh active Active
- 2005-02-04 AU AU2005210174A patent/AU2005210174B2/en active Active
- 2005-02-04 BR BRPI0506906-8A patent/BRPI0506906B1/pt not_active IP Right Cessation
- 2005-02-04 AT AT05707942T patent/ATE505186T1/de active
- 2005-02-04 DE DE602005027445T patent/DE602005027445D1/de active Active
- 2005-02-04 DK DK05707942.8T patent/DK1720531T3/da active
- 2005-02-04 US US11/050,441 patent/US7589208B2/en active Active
- 2005-02-04 ES ES05707942T patent/ES2364754T3/es active Active
- 2005-02-04 SI SI200531327T patent/SI1720531T1/sl unknown
- 2005-02-04 JP JP2006551857A patent/JP4864724B2/ja active Active
- 2005-02-04 NZ NZ548469A patent/NZ548469A/en unknown
-
2006
- 2006-06-12 IL IL176255A patent/IL176255A/en active IP Right Grant
- 2006-09-04 NO NO20063931A patent/NO337235B1/no not_active IP Right Cessation
-
2007
- 2007-10-17 HK HK07111206.0A patent/HK1105866A1/xx unknown
-
2011
- 2011-07-12 CY CY20111100676T patent/CY1111697T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0400235D0 (sv) | New composition containing quinoline compounds | |
MXPA03011039A (es) | Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos. | |
GEP20104964B (en) | 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof | |
MXPA04002647A (es) | Antranilamidas artropodicidas. | |
MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
WO2005021519A3 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
NO20054852L (no) | GFAT inhibitorer | |
TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
WO2008057775A3 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
GEP20074148B (en) | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | |
UA99494C2 (ru) | Производные пиридазинона, гербицидные композиции и способ контролирования роста нежелательной растительности | |
NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
SE0202463D0 (sv) | Novel compounds | |
UA99908C2 (ru) | Пиридопиразиновые производные, способ борьбы с растениями, гербицидные композиции | |
DK0931788T3 (da) | Metalloproteasehæmmere | |
WO2006125555A3 (de) | Chinazolinone | |
NO20064351L (no) | Caspaseinhibitorer og anvendelser derav | |
TW200745063A (en) | Triazolone derivatives | |
NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
TW200730507A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
SE9803773D0 (sv) | Compounds | |
MXPA04009421A (es) | Compuestos de tiazol-2-ilimina como inhibidores de la pde-7. | |
NO20064074L (no) | Pyrrolokinolin- og piperidinokinolinderivater, fremstilling derav, sammensetninger inneholdende disse og anvendelse derav |